Observational studyESMO open2026
Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study.
Observational study in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Analytical and Biological Factors Associated with Oncogenic Variant Yield in Tumor-Agnostic Plasma ctDNA Profiling.Diagnostics (Basel, Switzerland) · 2026Article
- Bronchoalveolar lavage fluidTranslational lung cancer research · 2026Article
- Sensitive Detection of Epidermal Growth Factor in Lung Cancer Patients by Electrochemical Biosensors.Analytical chemistry · 2026Article
- Advances in Liquid Biopsy for Precision Oncology: Applications, Challenges, and Future Directions in Clinical Laboratories.OncoTargets and therapy · 2026Review
- Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn metastatic non-small-cell lung cancer (NSCLC), tissue and plasma (liquid biopsy) testing are recommended complementary approaches to identify actionable gene mutations. In non-metastatic disease, the utility of liquid biopsy is less clear. This retrospective observational study assessed the effectiveness of liquid biopsy to detect epidermal growth factor receptor (EGFR) mutations in stage IIIA/IIIB/IIIC NSCLC against tissue biopsy. PATIENTS AND
methodsData from a US nationwide electronic health record-derived deidentified database of patients with NSCLC and liquid and tissue biopsy test results for EGFR mutations were analyzed from time of stage III NSCLC diagnosis (1 January 2017 to 31 August, 2023) until the data cut-off or date of metastasis (if the tumor metastasized). Objectives were to assess concordance and performance of liquid and tissue biopsy tests for the detection of EGFR mutations.
resultsData were analyzed from 425 patients. Some 43%, 41%, and 9% of patients had stage IIIA, IIIB, and IIIC NSCLC, respectively; 27% had unresectable NSCLC. For all EGFR mutation testing methods, median time between specimen collection and test result availability was 8 days for liquid biopsy (n = 494) and 32 days for tissue biopsy (n = 499); 25 (5%) and 41 (8%) samples, respectively, detected EGFR mutations. The concordance rate was 93% overall and was greater for tests conducted in 2020-2023 (96%) than 2017-2019 (87%). Specificity and sensitivity of liquid biopsy were 98% and 45%, respectively. Next-generation sequencing (NGS) was the most common biopsy testing method (liquid, 74%; tissue, 67%). For NGS tests only, concordance was 94% (2020-2023, 96%; 2017-2019, 85%), with a specificity and sensitivity of 99% and 53%, respectively.
conclusionsLiquid biopsy may complement tissue biopsy in detection of EGFR mutations in stage III NSCLC. Using current NGS technology, EGFR mutation status was identified with high specificity. Further research is warranted to confirm the utility of liquid biopsy for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.